Real-world walking in multiple sclerosis: Separating capacity from behavior
- PMID: 29078135
- PMCID: PMC5695705
- DOI: 10.1016/j.gaitpost.2017.10.015
Real-world walking in multiple sclerosis: Separating capacity from behavior
Abstract
Background: Habitual physical activity (HPA) measurement addresses the impact of MS on real-world walking, yet its interpretation is confounded by the competing influences of MS-associated walking capacity and physical activity behaviors.
Objective: To develop specific measures of MS-associated walking capacity through statistically sophisticated HPA analysis, thereby more precisely defining the real-world impact of disease.
Methods: Eighty-eight MS and 38 control subjects completed timed walks and patient-reported outcomes in clinic, then wore an accelerometer for 7days. HPA was analyzed with several new statistics, including the maximum step rate (MSR) and habitual walking step rate (HWSR), along with conventional methods, including average daily steps. HPA statistics were validated using clinical walking outcomes.
Results: The six-minute walk (6MW) step rate correlated most strongly with MSR (r=0.863, p<10-25) and HWSR (r=0.815, p<10-11) rather than average daily steps (r=0.676, p<10-11). The combination of MSR and HWSR correlated more strongly with the 6MW step rate than either measure alone (r=0.884, p<10-14). The MSR overestimated the 6MW step rate (μ=10.4, p<10-7), whereas the HWSR underestimated it (μ=-18.2, p<10-19).
Conclusions: Conventional HPA statistics are poor measures of capacity due to variability in activity behaviors. The MSR and HWSR are valid, specific measures of real-world capacity which capture subjects' highest step rate and preferred step rate, respectively.
Keywords: Accelerometry; Gait disorders/ataxia; Habitual physical activity; Habitual walking performance; Multiple sclerosis; Outcomes research; Six-Minute walk.
Copyright © 2017 Elsevier B.V. All rights reserved.
Conflict of interest statement
MME, SDP, and JCL have nothing to report. MDG reports grants from Biogen Idec, grants from Novartis, other from Acorda, other from Biogen Idec, other from Novartis, personal fees from Novartis, and personal fees from Sarepta outside the submitted work.
Figures
References
-
- Goldman MD, Motl RW, Rudick RA. Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. [Accessed July 29, 2016];Ther Adv Neurol Disord. 2010 3(4):229–239. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21179614. - PMC - PubMed
-
- Nero H, Wallén MB, Franzén E, Ståhle A, Hagströmer M. Accelerometer cut points for physical activity assessment of older adults with Parkinson’s disease. Gonzalez-Alegre P, editor. [Accessed July 29, 2016];PLoS One. 2015 10(9):e0135899. Available at: http://dx.plos.org/10.1371/journal.pone.0135899. - DOI - PMC - PubMed
-
- Sun F, Norman IJ, While AE. Physical activity in older people: a systematic review. [Accessed July 29, 2016];BMC Public Health. 2013 13(1):449. Available at: http://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-13-449. - DOI - PMC - PubMed
-
- Troiano RP, Berrigan D, Dodd KW, et al. Physical activity in the United States measured by accelerometer. Med. Sci. Sports Exerc. 2008;40(1):181–188. - PubMed
-
- Giles-Corti B, Donovan RJ. The relative influence of individual, social and physical environment determinants of physical activity. Soc. Sci. Med. 2002;54(12):1793–1812. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
